Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis

Company Overview

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with cardiovascular disease. The company’s lead product candidate is tecarfarin, an investigational oral anticoagulant intended for people who require long-term blood-thinning treatment, including patients with implanted mechanical heart valves and left ventricular assist devices.

Tecarfarin is designed as a vitamin K antagonist and is metabolized primarily through carboxylesterase 1 rather than the cytochrome P450 pathway associated with many drug interactions involving warfarin. Cadrenal is evaluating whether this mechanism may offer a treatment alternative for patients who face challenges with existing anticoagulant therapies. Tecarfarin has not been approved for commercial use, and its safety and effectiveness remain subject to clinical development and regulatory review.

Cadrenal Therapeutics was established to advance tecarfarin and related cardiovascular applications. The company is headquartered in Ponte Vedra Beach, Florida, and is led by Quang Pham, who serves as chairman and chief executive officer. Its activities are centered on research, clinical development, regulatory engagement and potential commercialization of therapies for specialized cardiovascular patient populations.

Key Stats

• Today's Range: $0.92 to $1.10
• 50-Day Range: $0.87 to $1.95
• 52-Week Range: $0.82 to $14.35
• Volume: 344,292 shs
• Average Volume: 210,363 shs
• Market Capitalization: $3.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Hold

Cadrenal Therapeutics Stock Analysis - MarketRank™

Cadrenal Therapeutics scored higher than 57% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Cadrenal Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Cadrenal Therapeutics has a consensus price target of $13.00, representing about 1,174.5% upside from its current price of $1.02.

Amount of Analyst Coverage

Cadrenal Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cadrenal Therapeutics are expected to grow in the coming year, from ($3.86) to ($3.01) per share.

Price to Book Value per Share Ratio

Cadrenal Therapeutics has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.48% of the float of Cadrenal Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cadrenal Therapeutics has a short interest ratio ("days to cover") of 1.08, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cadrenal Therapeutics has recently decreased by 10.82%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cadrenal Therapeutics does not currently pay a dividend.

Dividend Growth

Cadrenal Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: N/A

News Sentiment

Cadrenal Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Cadrenal Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for CVKD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cadrenal Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.59% of the stock of Cadrenal Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

7.92% of the stock of Cadrenal Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CVKD
• CIK: 1937993
• Web: www.cadrenal.com
• Phone: 904-300-0701
• Fax: N/A
• Employees: 5
• Year Founded: 2022

Price Target and Rating

• Average Price Target for Cadrenal Therapeutics: $13.00
• High Price Target: $13.00
• Low Price Target: $13.00
• Potential Upside/Downside: +1,174.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.24 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -406.41%
• Return on Assets: -273.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.73
• Quick Ratio: 3.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.17 per share
• Price / Book: 0.87

Miscellaneous

• Outstanding Shares: 3,570,000
• Free Float: 3,047,000
• Market Cap: $3.64 million
• Optionable: Not Optionable
• Beta: 1.93